Hepatitis Forums

Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on January 10, 2020, 11:16:07 am

Title: Selgantolimod Shows Promise as Treatment for Hepatitis B
Post by: Hep Editors on January 10, 2020, 11:16:07 am
Gilead Sciences’ selgantolimod (GS-9688), a potent and selective oral agonist of toll-like receptor 8 (TLR8) was safe and well tolerated as a treatment for hepatitis B virus (HBV) in a mid-stage trial, with a small number of participants experiencing key benchmarks of combatting the virus.

Edward Gane, MD, of the Auckland City Hospital in New Zealand, presented findings from a randomized, double-blind, placebo-controlled, multicenter Phase II trial of selgantolimod at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, this month in Boston.